期刊
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
卷 30, 期 10, 页码 759-766出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/jir.2010.0091
关键词
-
This review discusses type I interferon (IFN) immunogenicity with focus on methods of detection of anti-IFN antibodies in patients treated with human recombinant IFN-beta. Pitfalls involved in the clinical use of various types of assays for binding antibodies and neutralizing antibodies against IFN-beta are presented, and the widely held distinction between binding antibodies and neutralizing antibodies is questioned both in terms of detection and clinical importance. The article also addresses important bioavailability and pharmacokinetic issues occurring with prolonged use of protein drugs. The rationale for individualized or personalized medicine, ie, optimizing therapies according to individual needs rather than using standardized trial-and-error regimens to all patients, is highlighted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据